Anktiva’s FDA Approval Now Includes Papillary-Only Bladder Cancer: Who Is Eligible?
Bottom line: On 14 October 2026, the U.S. Food and Drug Administration expanded the indication for Anktiva (nogapendekin alfa inbakicept-pmln) used with BCG. The added group is adults with BCG-unresponsive, high-grade, papillary-only non-muscle-invasive bladder cancer. This is not an approval for every type of bladder cancer or for everyone starting BCG.
Which patients were added to the U.S. indication?
The previous indication covered BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS), whether or not papillary tumors were also present. The expansion includes high-grade papillary tumors without CIS. Non-muscle-invasive means the cancer has not grown into the bladder muscle. Establishing tumor grade, whether CIS is present, and whether disease meets BCG-unresponsive criteria requires pathology and treatment records—not a headline alone.
This is a U.S. FDA decision. It does not itself establish authorization, reimbursement, or supply in South Korea or any other country. People receiving care outside the United States need to check the applicable local regulatory status with their care team.
Was the 62% response rate measured in the newly added group?
No. The pivotal evidence summarized by FDA came from Cohort A of QUILT-3.032, a single-arm, multicenter study involving 77 patients whose BCG-unresponsive disease included CIS, with or without papillary tumors. In that cohort, the complete response rate was 62% (95% confidence interval 51%–73%). Among responders, 58% maintained a response for at least 12 months and 40% for at least 24 months.
Those figures should not be presented as a directly measured response rate for patients with papillary-only disease. FDA considered clinical and non-clinical similarities between high-grade papillary tumors and CIS, their frequent coexistence, and their risks after BCG failure. It concluded that the earlier efficacy evidence could be extrapolated to the newly included group. This is the central evidence distinction behind the approval.
What cautions still matter?
FDA lists common adverse reactions and laboratory abnormalities including painful or frequent urination, blood in the urine, urinary tract infection, fever, chills, and increases in creatinine or potassium. The prescribing information also warns that delaying cystectomy may allow metastatic bladder cancer to develop, which can be fatal. Approval therefore does not guarantee benefit for an individual or mean that surgery can safely be postponed.
For a person with bladder cancer, useful questions for the treating team include whether the pathology shows CIS or high-grade papillary-only disease, whether prior BCG treatment meets the unresponsive definition, what alternatives and surveillance are relevant, and whether Anktiva plus BCG is available under local rules. This article is not a recommendation to start, stop, or delay any treatment.
Scope and evidence at a glance
- Decision date and authority: U.S. FDA, 14 October 2026
- Added population: adults with BCG-unresponsive, high-grade, papillary-only non-muscle-invasive bladder cancer
- Geography: U.S. indication; access elsewhere requires separate confirmation
- Evidence limit: the reported 62% complete response arose in a CIS-containing study cohort, not from direct measurement in the newly added papillary-only population
Written by: Life Choice Note, an independent health-information explainer. Sources reviewed: 15 October 2026. This information is not individualized medical advice.